313 related articles for article (PubMed ID: 8624578)
21. Dissemination risk index based on plasminogen activator system components in primary breast cancer.
Bouchet C; Hacène K; Martin PM; Becette V; Tubiana-Hulin M; Lasry S; Oglobine J; Spyratos F
J Clin Oncol; 1999 Oct; 17(10):3048-57. PubMed ID: 10506599
[TBL] [Abstract][Full Text] [Related]
22. Tumour-associated urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in normal and neoplastic tissues of patients with squamous cell cancer of the oral cavity - clinical relevance and prognostic value.
Hundsdorfer B; Zeilhofer HF; Bock KP; Dettmar P; Schmitt M; Kolk A; Pautke C; Horch HH
J Craniomaxillofac Surg; 2005 Jun; 33(3):191-6. PubMed ID: 15878520
[TBL] [Abstract][Full Text] [Related]
23. Clinical value of extended biologic staging by bone marrow micrometastases and tumor-associated proteases in gastric cancer.
Heiss MM; Allgayer H; Gruetzner KU; Babic R; Jauch KW; Schildberg FW
Ann Surg; 1997 Dec; 226(6):736-44; discussion 744-5. PubMed ID: 9409572
[TBL] [Abstract][Full Text] [Related]
24. Clinical relevance of uPA, uPAR, PAI 1 and PAI 2 tissue expression and plasma PAI 1 level in colorectal carcinoma patients.
Halamkova J; Kiss I; Pavlovsky Z; Jarkovsky J; Tomasek J; Tucek S; Hanakova L; Moulis M; Cech Z; Zavrelova J; Penka M
Hepatogastroenterology; 2011; 58(112):1918-25. PubMed ID: 22234062
[TBL] [Abstract][Full Text] [Related]
25. Urokinase plasminogen activator and plasminogen activator inhibitor type-1 in nonsmall-cell lung cancer: relation to prognosis and angiogenesis.
Offersen BV; Pfeiffer P; Andreasen P; Overgaard J
Lung Cancer; 2007 Apr; 56(1):43-50. PubMed ID: 17207889
[TBL] [Abstract][Full Text] [Related]
26. Cathepsin-D, urokinase plasminogen activator and type-1 plasminogen activator inhibitor in early breast cancer: an immunohistochemical study of prognostic value and relations to tenascin-C and other factors.
Jahkola T; Toivonen T; von Smitten K; Virtanen I; Wasenius VM; Blomqvist C
Br J Cancer; 1999 Apr; 80(1-2):167-74. PubMed ID: 10389993
[TBL] [Abstract][Full Text] [Related]
27. High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis.
Grøndahl-Hansen J; Christensen IJ; Rosenquist C; Brünner N; Mouridsen HT; Danø K; Blichert-Toft M
Cancer Res; 1993 Jun; 53(11):2513-21. PubMed ID: 8388317
[TBL] [Abstract][Full Text] [Related]
28. Prognostic impact of urokinase-type plasminogen activator system components in clear cell renal cell carcinoma patients without distant metastasis.
Fuessel S; Erdmann K; Taubert H; Lohse-Fischer A; Zastrow S; Meinhardt M; Bluemke K; Hofbauer L; Fornara P; Wullich B; Baretton G; Magdolen V; Wirth MP; Kotzsch M
BMC Cancer; 2014 Dec; 14():974. PubMed ID: 25519168
[TBL] [Abstract][Full Text] [Related]
29. [Correlation between the expression of urokinase-type plasminogen activator, E-cadherin and malignancy in gastric cancer].
Itoh H; Yonemura Y; Tsuchihara K; Kawamura T; Nojima N; Kaji M; Fushida S; Nishimura G; Fujimura T; Miwa K
Gan To Kagaku Ryoho; 1995 Jun; 22 Suppl 2():124-9. PubMed ID: 7611774
[TBL] [Abstract][Full Text] [Related]
30. Clinical significance of urokinase-type plasminogen activator (uPA) and its type-1 inhibitor (PAI-1) for metastatic sentinel lymph node involvement in breast cancer.
Harms W; Malter W; Krämer S; Drebber U; Drzezga A; Schmidt M
Anticancer Res; 2014 Aug; 34(8):4457-62. PubMed ID: 25075085
[TBL] [Abstract][Full Text] [Related]
31. Her-2/neu and urokinase-type plasminogen activator and its inhibitor in breast cancer.
Konecny G; Untch M; Arboleda J; Wilson C; Kahlert S; Boettcher B; Felber M; Beryt M; Lude S; Hepp H; Slamon D; Pegram M
Clin Cancer Res; 2001 Aug; 7(8):2448-57. PubMed ID: 11489825
[TBL] [Abstract][Full Text] [Related]
32. Clinical relevance of invasion factors urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 for individualized therapy decisions in primary breast cancer is greatest when used in combination.
Harbeck N; Kates RE; Schmitt M
J Clin Oncol; 2002 Feb; 20(4):1000-7. PubMed ID: 11844823
[TBL] [Abstract][Full Text] [Related]
33. Expression of urokinase-type plasminogen activator receptor and plasminogen activator inhibitor-1 in gastric cancer.
Kawasaki K; Hayashi Y; Wang Y; Suzuki S; Morita Y; Nakamura T; Narita K; Doe W; Itoh H; Kuroda Y
J Gastroenterol Hepatol; 1998 Sep; 13(9):936-44. PubMed ID: 9794194
[TBL] [Abstract][Full Text] [Related]
34. The urokinase-type plasminogen activator and inhibitors in resectable lung adenocarcinoma.
Zhu C; Jiang L; Xu J; Ren A; Ju F; Shu Y
Pathol Res Pract; 2020 Apr; 216(4):152885. PubMed ID: 32113794
[TBL] [Abstract][Full Text] [Related]
35. Larger and more invasive colorectal carcinoma contains larger amounts of plasminogen activator inhibitor type 1 and its relative ratio over urokinase receptor correlates well with tumor size.
Abe J; Urano T; Konno H; Erhan Y; Tanaka T; Nishino N; Takada A; Nakamura S
Cancer; 1999 Dec; 86(12):2602-11. PubMed ID: 10594855
[TBL] [Abstract][Full Text] [Related]
36. Impact of urokinase-type plasminogen activator and its inhibitor type 1 on prognosis in cervical cancer of the uterus.
Kobayashi H; Fujishiro S; Terao T
Cancer Res; 1994 Dec; 54(24):6539-48. PubMed ID: 7987854
[TBL] [Abstract][Full Text] [Related]
37. Combined evaluation of urokinase-type plasminogen activator and plasminogen activator inhibitor-2 expression in gastric carcinoma.
Maeda K; Chung Y; Sawada T; Ogawa Y; Onoda N; Nakata B; Kato Y; Sowa M
Int J Oncol; 1996 Mar; 8(3):499-503. PubMed ID: 21544388
[TBL] [Abstract][Full Text] [Related]
38. Strong prognostic impact of tumor-associated urokinase-type plasminogen activator in completely resected adenocarcinoma of the esophagus.
Nekarda H; Schlegel P; Schmitt M; Stark M; Mueller JD; Fink U; Siewert JR
Clin Cancer Res; 1998 Jul; 4(7):1755-63. PubMed ID: 9676852
[TBL] [Abstract][Full Text] [Related]
39. Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor and plasminogen activator inhibitors in patients with renal cell carcinoma: correlation with tumor associated macrophage and prognosis.
Ohba K; Miyata Y; Kanda S; Koga S; Hayashi T; Kanetake H
J Urol; 2005 Aug; 174(2):461-5. PubMed ID: 16006865
[TBL] [Abstract][Full Text] [Related]
40. Prognostic significance of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor (PAI-1) in patients with primary invasive ductal breast carcinoma - a 7.5-year follow-up study.
Jelisavac-Cosic S; Sirotkovic-Skerlev M; Kulic A; Jakic-Razumovic J; Kovac Z; Vrbanec D
Tumori; 2011; 97(4):532-9. PubMed ID: 21989445
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
